Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment

Abstract

The Korean Society of Heart Failure (KSHF) guidelines aim to provide physicians with evidence-based recommendations for the management of patients with heart failure (HF). After the first introduction of the KSHF guidelines in 2016, newer therapies for HF with reduced ejection fraction, HF with mildly reduced ejection fraction, and HF with preserved ejection fraction have since emerged. The current version has been updated based on international guidelines and research data on Korean patients with HF. Herein, we present Part II of these guidelines, which comprises treatment strategies to improve the outcomes of patients with HF.

Effectiveness of a Smartphone App–Based Intervention With Bluetooth-Connected Monitoring Devices and a Feedback System in Heart Failure (SMART-HF Trial): Randomized Controlled Trial

“…Support for facilitating self-care is crucial for patients with HF [ 18 - 20 ]. However, proper patient self-care and delivery of health care provider feedback are challenging to implement in a real-world clinical setting because of the required time, financial, and human resources.…”

“…Follow-up visits were scheduled at 2 (visit 2, optional) and 4 (visit 3) weeks after randomization. Both groups received standard care according to the current HF guidelines [ 20 , 32 ], and HF medication could be modified at the discretion of the treating physicians.…”

The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper

“…Of particular emphasis in the variable collection of the KorHF III registry, we sought to collect information on the use of angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are relatively new drugs in HF. 14 15 16) We also collected information on left ventricular assist devices, which have been increasingly utilized in Korea in recent years. In addition, we sought to collect information on the iron profile, including ferritin, serum iron and total iron binding capacity, as the diagnosis and treatment of iron deficiency in HF has been emphasized.…”

“…Concerns arose regarding the limited participation of high-volume centers in these registries, potentially leading to selection bias. Furthermore, with the evolution of HF guidelines and the introduction of new pharmacological and non-pharmacological treatments, 5 14 15 16) the previous registries did not capture these advancements.…”

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF

“…Current guidelines recommend the use of SGLT2i as first line treatment for patients with HFmrEF with a class of evidence IA in the ESC guideline, 2) class IIA in the American College of Cardiology and American Heart Association guidelines, 7) and class Ib in the Korean Society of Heart Failure Guidelines 8) for patients with HFmrEF and HFpEF. The guidelines also recommend uptitration of guideline-directed medical therapies proven efficacious in HFrEF, such as renin-angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitor (ARNI), beta blockers, and mineralocorticoid receptor antagonists with a low level of evidence (IIB).…”